ACLX
Arcellx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.73B
P/E Ratio
—
EPS
$-4.07
Beta
0.25
52W High
$115.13
52W Low
$47.86
50-Day MA
$110.81
200-Day MA
$83.72
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
61.73
PEG Ratio
—
About Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | $22.29M |
| Gross Profit (TTM) | $-135.32M |
| EBITDA | $-246.40M |
| Operating Margin | -3850.00% |
| Return on Equity | -53.40% |
| Return on Assets | -24.00% |
| Revenue/Share (TTM) | $0.40 |
| Book Value | $6.95 |
| Price-to-Book | 16.73 |
| Price-to-Sales (TTM) | 302.04 |
| EV/Revenue | 284.21 |
| EV/EBITDA | -6.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -89.20% |
| Shares Outstanding | $58.51M |
| Float | $42.96M |
| % Insiders | 11.67% |
| % Institutions | 90.33% |
Analyst Ratings
Consensus ($112.20 target)
18
HoldMore HEALTHCARE Stocks
Data last updated: 5/2/2026